| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Related party collaboration receivable | NaN | -700 | 0 | 175 |
| Net loss | -27,937 | -27,426 | -27,892 | -64,403 |
| Loss on disposal of fixed assets | NaN | -62 | 0 | -79 |
| Stock-based compensation expense | 2,488 | 3,521 | 3,460 | 7,806 |
| Depreciation | 932 | 1,049 | 932 | 2,079 |
| Amortization of premiums and discounts on marketable securities | 365 | 530 | 654 | 1,789 |
| Non-cash lease expense | 1,269 | 1,262 | 1,233 | 2,376 |
| Accounts receivable | -267 | -1,425 | 1,512 | 170 |
| Prepaid expenses and other current assets | -471 | -2,290 | -3,153 | 1,826 |
| Accounts payable | -2,290 | 2,897 | 312 | -2,192 |
| Accrued expenses | -5,126 | -3,185 | 2,831 | -2,146 |
| Operating lease liabilities | -1,933 | -1,869 | -1,836 | -3,522 |
| Deferred revenue | -1,195 | -10,459 | -11,075 | -7,273 |
| Net cash used in operating activities | -33,419 | -30,263 | -31,048 | -71,156 |
| Proceeds from sales and maturities of marketable securities | NaN | NaN | 41,731 | 159,687 |
| Purchases of property and equipment | 14 | 626 | 207 | 1,763 |
| Purchases of marketable securities | 43,441 | 12,503 | 6,636 | 114,790 |
| Proceeds from sales and maturities of marketable securities | 51,556 | 261,971 | NaN | NaN |
| Net cash provided by investing activities | 8,101 | 47,424 | 34,888 | 43,134 |
| Proceeds from the exercise of stock options | 294 | 21 | 85 | 161 |
| Proceeds from the purchase of common stock under espp | NaN | 115 | 0 | 434 |
| Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs | 3,038 | NaN | NaN | NaN |
| Net cash provided by financing activities | 3,332 | 136 | 85 | 595 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -21,986 | 17,297 | 3,925 | -27,427 |
| Cash, cash equivalents, and restricted cash, beginning of period | 68,036 | 50,739 | 74,241 | NaN |
| Cash, cash equivalents, and restricted cash, end of period | 46,050 | 68,036 | 50,739 | NaN |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)